share_log

Entheon Biomedical Announces Non-Brokered Private Placement Financing

Benzinga Real-time News ·  Apr 6, 2022 03:50

Entheon Biomedical Corp. (OTCQB:ENTBF) announced a non-brokered private placement financing for up to 30,000,000 Units at a price of CDN$0.10 per unit, for gross proceeds of up to CDN$3,000,000.
Each unit will consist of one common share in the capital of the company and one transferable share purchase warrant. Each warrant will be exercisable to acquire one additional share for a period of 36 months from the date of issue. The exercise price will be CDN$0.15 per share in year one, and CDN$0.25 in the two following years.
According to the company, the goal of the private placement is to finance research and development activities, general working capital and corporate purposes with its proceedings.
Earlier this year, Entheon had announced the approval by Dutch authorities of a Phase 1 clinical trial on DMT.

Photo by micheile on Unsplash

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment